[EN] SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS<br/>[FR] COMPOSÉS SPIROCYCLIQUES EN TANT QU'INHIBITEURS DE LA TRYPTOPHANE HYDROXYLASE
申请人:KAROS PHARMACEUTICALS INC
公开号:WO2015035113A1
公开(公告)日:2015-03-12
The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
Synthesis and Characterization of Chiral Benzylic Ether‐Bridged Periodic Mesoporous Organosilicas
作者:Jürgen Morell、Sangam Chatterjee、Peter J. Klar、Daniel Mauder、Ilja Shenderovich、Frank Hoffmann、Michael Fröba
DOI:10.1002/chem.200800239
日期:2008.6.27
The first synthesis of a chiralperiodic mesoporous organosilica (PMO) carrying benzylic ether bridging groups is reported. By hydrolysis and condensation of the new designed chiralorganosilica precursor 1,4-bis(triethoxysilyl)-2-(1-methoxyethyl)benzene (BTEMEB) in the presence of the non-ionic oligomeric surfactant Brij 76 as supramolecular structure-directing agent under acidic conditions, an ordered
SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS
申请人:Karos Pharmaceuticals, Inc.
公开号:US20150080393A1
公开(公告)日:2015-03-19
The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
Spirocyclic compounds as tryptophan hydroxylase inhibitors
申请人:Karos Pharmaceuticals, Inc.
公开号:US09199994B2
公开(公告)日:2015-12-01
The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.